Seagen 관리

관리 기준 확인 2/4

Seagen CEO는 David Epstein, Nov2022 에 임명되었습니다 의 임기는 1.08 년입니다. 총 연간 보상은 $ 58.59M, 0.3% 로 구성됩니다. 0.3% 급여 및 99.7% 보너스(회사 주식 및 옵션 포함). 는 $ 3.75M 가치에 해당하는 회사 주식의 0.009% 직접 소유합니다. 3.75M. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 9.9 년입니다.

주요 정보

David Epstein

최고 경영자

US$58.6m

총 보상

CEO 급여 비율	0.3%
CEO 임기	1.1yrs
CEO 소유권	0.009%
경영진 평균 재임 기간	2.4yrs
이사회 평균 재임 기간	9.9yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

David Epstein 의 보수는 Seagen 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2023	n/a	n/a	-US$750m
Jun 30 2023	n/a	n/a	-US$725m
Mar 31 2023	n/a	n/a	-US$649m
Dec 31 2022	US$59m	US$190k	-US$610m

보상 대 시장: David 의 총 보상 ($USD 58.59M )은 UK 시장( $USD 5.66M ).

보상과 수익: David 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

David Epstein (61 yo)

1.1yrs

테뉴어

US$58,588,196

보상

Mr. David R. Epstein, B.Sc., M.B.A., serves as Chief Executive Officer and Director at Seagen Inc. since November 9, 2022. He served as an Independent Director at Senti Biosciences, Inc. since June 09, 202...

리더십 팀

이름	위치	테뉴어	보상	소유권
David Epstein	CEO & Director	1.1yrs	US$58.59m	0.0087% $ 3.8m
Todd Simpson	Chief Financial Officer	18.2yrs	US$5.71m	0.049% $ 21.3m
Vaughn Himes	Chief Technical Officer	7.3yrs	US$4.54m	0.071% $ 30.7m
Jean I. Liu	Chief Legal Officer & Corporate Secretary	9.1yrs	US$5.95m	0.026% $ 11.2m
Charles Romp	Executive Vice President of Commercial U.S.	3.7yrs	US$5.03m	0.037% $ 15.8m
Roger Dansey	Chief Medical Officer and President of Research & Development	1.1yrs	US$36.39m	0.020% $ 8.8m
William Compton	Senior VP of Global Information Technology & CIO	less than a year	데이터 없음	데이터 없음
David Caouette	Vice President of Corporate Communications	no data	데이터 없음	데이터 없음
Matt Skelton	Vice President of Marketing	8.1yrs	데이터 없음	데이터 없음
Peggy Pinkston	Chief Human Resources Officer	less than a year	데이터 없음	데이터 없음
Natasha Hernday	Chief Business Officer	1.2yrs	데이터 없음	데이터 없음
Megan O'Meara	Head of Early Stage Development & VP	no data	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 관리: 0A8R 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
David Epstein	CEO & Director	1.1yrs	US$58.59m	0.0087% $ 3.8m
John Orwin	Independent Director	9.9yrs	US$468.53k	0.015% $ 6.6m
David Gryska	Independent Director	18.8yrs	US$483.53k	0.026% $ 11.2m
Daniel Welch	Independent Director	16.5yrs	US$468.53k	0.0082% $ 3.5m
Felix Baker	Independent Chair of the Board	20.4yrs	US$528.53k	0.022% $ 9.5m
Ted Love	Independent Director	3.3yrs	US$471.03k	0.0025% $ 1.1m
Nancy Simonian	Independent Director	11.8yrs	US$474.53k	0.033% $ 14.4m
Alpna Seth	Independent Director	5.8yrs	US$471.03k	0.0069% $ 3.0m
Sandra Swain	Independent Director	1.1yrs	US$214.73k	데이터 없음

9.9yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: 0A8R 의 이사회는 경험(평균 재직 기간 9.9 년)으로 간주됩니다.

Seagen 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Independent Director recently sold US$968k worth of stock

Seagen Announces Resignation of Clay Siegall as CEO

Seagen Inc., Annual General Meeting, May 13, 2022

Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence

Insufficient new directors

Seagen Inc. Announces Executive Changes

Recent updates

Seagen Inc. Files Form 15

Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index (USD)

Pfizer Inc. (NYSE:PFE) completed the acquisition of Seagen Inc. (NasdaqGS:SGEN) from Baker/Tisch Investments, L.P, a funds managed by Baker Brothers Investments and others.

Seagen Inc. Announces Phase 2 Study Evaluating the Antibody-Drug Conjugate ADCETRIS (brentuximab Vedotin) in Combination with the PD-1 Inhibitor Nivolumab and Standard Chemotherapy Agents Doxorubicin and Dacarbazine

Seagen Inc. Announces Data from the Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA

Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer

Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Third quarter 2023 earnings released: US$1.15 loss per share (vs US$1.03 loss in 3Q 2022)

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Seagen Inc. Announces to Highlight Overall Survival Data for Padcev and Tivdak During Presidential Symposium At Esmo Congress 2023

Seagen Inc. to Report Q3, 2023 Results on Nov 01, 2023

Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Seagen Inc. Announces Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA®? (tucatinib) in Combination with Antibody-Drug Conjugate Ado-Trastuzumab Emtansine

Second quarter 2023 earnings released: US$1.13 loss per share (vs US$0.73 loss in 2Q 2022)

Seagen Inc. to Report Q2, 2023 Results on Aug 02, 2023

Seagen Inc. Announces Phase 3 Trial of Adcetris (Brentuximab Vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% Vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma

Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)

First quarter 2023 earnings released: US$0.94 loss per share (vs US$0.74 loss in 1Q 2022)

Full year 2022 earnings released: US$3.31 loss per share (vs US$3.71 loss in FY 2021)

Seagen Inc. to Report Q4, 2022 Results on Feb 15, 2023

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Seagen Inc. Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma

Independent Director recently sold US$968k worth of stock

Seagen Inc. Announces U.S. FDA Approval of New Indication for Adcetris® (Brentuximab Vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma

Third quarter 2022 earnings released: US$1.03 loss per share (vs US$1.61 loss in 3Q 2021)

Seagen Inc. Revises Revenue Guidance for the Full Year of 2022

Seagen Inc. to Report Q3, 2022 Results on Oct 27, 2022

Seagen Inc. Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer

Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (Enfortumab Vedotin-Ejfv) with KEYTRUDA((R) (Pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

Seagen to Highlight Research in Urothelial and Colorectal Cancers At 2022 European Society for Medical Oncology (Esmo) Congress

Merck’s Reportedly Talks to Acquire Seagen Hit Snag, Threatening Mega Pharma Deal

Arbitrator Rules in Favor of Daiichi Sankyo Company, Limited in Dispute with Seagen Inc

Second quarter 2022 earnings released: US$0.73 loss per share (vs US$0.47 loss in 2Q 2021)

Seagen Inc. Revises Earnings Guidance for the Year 2022

Seagen Inc. to Report Q2, 2022 Results on Jul 28, 2022

Merck Reportedly in Advanced Talks to Buy Seagen

Seagen Inc. Announces Full Results from the Pivotal Phase 2 MOUNTAINEER Trial, Which Showed TUKYSA (Tucatinib) in Combination with Trastuzumab

Merck Reportedly Pushes Forward with Potential Deal for Seagen

Merck, Other Suitors Reportedly Interested in Acquiring Seagen

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Takeda Pharmaceutical Company Limited and Seagen Inc. to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma

Seagen Inc. Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA(R) (tucatinib) in Combination with Trastuzumab in HER2-Positive Metastatic Colorectal Cancer

Seagen Announces Resignation of Clay Siegall as CEO

Seagen Inc., Annual General Meeting, May 13, 2022

Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence

First quarter 2022 earnings released: US$0.74 loss per share (vs US$0.67 loss in 1Q 2021)

Insufficient new directors

Astellas Pharma Inc. and Seagen Inc. Announces European Commission Approves PADCEV™ (Enfortumab Vedotin) for Locally Advanced or Metastatic Urothelial Cancer

Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting

Seagen Inc. to Report Q1, 2022 Results on Apr 28, 2022

Astellas Pharma Inc. and Seagen Inc. Announce CHMP Confirms Positive Opinion for PADCEV™ (Enfortumab Vedotin) in Locally Advanced or Metastatic Urothelial Cancer

Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma

Seagen and Astellas Announce Initial Results of PADCEV (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Seagen Inc. Provides Earnings Guidance for the Year 2022

ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma

Seagen Inc. Announces Executive Changes

Seagen Canada Announces Availability of PADCEV® to Treat Advanced Bladder Cancer

Seagen Inc. Announces Data from Phase I Clinical Trial Combining SEA-CD40

Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer

Seagen Announces Preliminary Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin)

Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA® (tucatinib)

Third quarter 2021 earnings released: US$1.61 loss per share (vs US$3.65 profit in 3Q 2020)

Seagen Inc. Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer

Japan’s MHLW Approves Astellas Pharma Inc. and Seagen Inc.'s PADCEV (enfortumab vedotin) for Advanced Urothelial Cancer

CEO 보상 분석

CEO